[1]王 雪,章 晔,李宝华.孟鲁斯特钠片与异丙托溴铵和布地奈德混悬液雾化吸入对小儿呼吸道感染性咳嗽的临床疗效[J].医学信息,2022,35(12):190-192.[doi:10.3969/j.issn.1006-1959.2022.12.049]
　WANG Xue,ZHANG Ye,LI Bao-hua.Clinical Effect of Montelukast Sodium Tablets Combined with Ipratropine Bromide and Budesonide Mixed Suspension Atomization Inhalation on Children with Respiratory Tract Infection Cough[J].Medical Information,2022,35(12):190-192.[doi:10.3969/j.issn.1006-1959.2022.12.049]
点击复制

孟鲁斯特钠片与异丙托溴铵和布地奈德混悬液雾化吸入对小儿呼吸道感染性咳嗽的临床疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年12期
页码:
190-192
栏目:
药物与临床
出版日期:
2022-06-15

文章信息/Info

Title:
Clinical Effect of Montelukast Sodium Tablets Combined with Ipratropine Bromide and Budesonide Mixed Suspension Atomization Inhalation on Children with Respiratory Tract Infection Cough
文章编号:
1006-1959（2022）12-0190-03
作者:
王 雪; 章 晔; 李宝华
（1.南京市浦口区中心医院儿科，江苏 南京 211800；2.江苏省妇幼保健院儿科，江苏 南京 211800）
Author(s):
WANG Xue; ZHANG Ye; LI Bao-hua
(1.Department of Pediatrics,Nanjing Pukou District Central Hospital,Nanjing 211800,Jiangsu,China;2.Department of Pediatrics,Jiangsu Maternal and Child Health Hospital,Nanjing 211800,Jiangsu,China)
关键词:
孟鲁斯特钠片; 异丙托溴铵; 布地奈德; 雾化吸入; 呼吸道感染性咳嗽
Keywords:
Montelukast sodium tablets; Ipratropium bromide; Budesonide; Atomizing inhalation; Respiratory tract infectious cough
分类号:
R725.6
DOI:
10.3969/j.issn.1006-1959.2022.12.049
文献标志码:
A
摘要:
目的 观察孟鲁斯特钠片与异丙托溴铵和布地奈德混悬液雾化吸入治疗小儿呼吸道感染性咳嗽的临床疗效。方法 选取2020年6月-2021年6月在南京市浦口区中心医院治疗的106例小儿呼吸道感染性咳嗽患儿为研究对象，采用随机数字表法分为对照组和观察组，各53例。对照组给予孟鲁斯特钠片治疗，观察组在对照组基础上给予异丙托溴铵和布地奈德混悬液治疗。比较两组临床疗效、临床症状消失时间和评分、复发率，以及不良反应发生情况。结果 观察组治疗总有效率为94.34%，高于对照组的83.02%，差异有统计学意义（P＜0.05）；观察组咳嗽、咳痰、咽痒症状消失时间均短于对照组，差异有统计学意义（P＜0.05）；观察组咳嗽、咳痰、咽痒症状评分均低于对照组，差异有统计学意义（P＜0.05）；随访2个月，观察组复发率为3.77%，低于对照组的9.43%，差异有统计学意义（P＜0.05）；观察组不良反应发生率为1.89%，与对照组的3.77%比较，差异无统计学意义（P＞0.05）。结论 孟鲁斯特钠片与异丙托溴铵和布地奈德混悬液雾化吸入治疗效果理想，可提高总有效率，缩短症状消失时间，改善临床症状，降低复发率及不良反应发生率。
Abstract:
Objective To observe the clinical efficacy of montelukast sodium tablets combined with ipratropium bromide and budesonide mixed suspension atomization inhalation in the treatment of children with respiratory tract infection cough.Methods A total of 106 children with respiratory tract infectious cough treated in Nanjing Pukou District Central Hospital from June 2020 to June 2021 were selected as the research subjects. They were divided into control group and observation group by random number table method, with 53 cases in each group. The control group was treated with montelukast sodium tablets, and the observation group was treated with ipratropium bromide and budesonide suspension on the basis of the control group. The clinical efficacy, disappearance time and score of clinical symptoms, recurrence rate, and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 94.34%, which was higher than 83.02% of the control group, and the difference was statistically significant (P<0.05). The disappearance time of cough, expectoration and pharyngeal itching in the observation group was shorter than that in the control group, and the difference was statistically significant (P<0.05). The scores of cough, expectoration and pharyngeal itching in the observation group were lower than those in the control group, and the difference was statistically significant (P<0.05). After two months of follow-up, the recurrence rate in the observation group was 3.77%, which was lower than 9.43% in the control group, and the difference was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was 1.89%, which was compared with 3.77% in the control group, the difference was not statistically significant (P>0.05).Conclusion The effect of montelukast sodium tablets combined with ipratropium bromide and budesonide suspension aerosol inhalation is ideal, which can improve the total effective rate, shorten the disappearance time of symptoms, improve clinical symptoms, reduce the recurrence rate and the incidence of adverse reactions.

参考文献/References:

[1]肖玲,阳进,刘颦,等.布地奈德联合复方异丙托溴铵雾化吸入治疗小儿急性喘息性支气管炎[J].西部医学,2017,29(12):1731-1732.[2]郭巍巍,严小桐,冯志山,等.呼吸道合胞病毒致儿童呼吸系统感染流行病学研究及免疫功能初步分析[J].中华微生物学和免疫学杂志,2020,40(2):140-145.[3]华琳,赵莲风.布地奈德与异丙托溴铵溶液雾化吸入治疗小儿麻疹合并支气管肺炎疗效观察[J].实用临床医药杂志,2016,20(22):201-202.[4]李凌,苏秋玉,常丽媛.孟鲁司特口服联合吸入用复方异丙托溴铵溶液雾化吸入治疗儿童感染后咳嗽临床观察[J].医学综述,2016,22(13):2663-2665.[5]康立,袁晴,李月琴.术前布地奈德混悬液雾化吸入治疗后对合并上呼吸道感染的小儿喉罩全麻期间呼吸不良事件的影响[J].临床与病理杂志,2016,36(11):1780-1783.[6]黄芳,唐林芬,司马燕.布地奈德联合复方异丙托溴铵雾化吸入治疗儿童支气管肺炎的疗效观察[J].实用临床医药杂志,2017,21(11):180-181.[7]乔凌燕,刘玉圣,刘颖,等.布地奈德异丙托溴铵与沙丁胺醇联合氧气雾化治疗小儿喘息性肺炎的临床疗效分析[J].西部医学,2017,29(5):636-638.[8]肖晶晶,农华,韩琳,等.两种方式吸入布地奈德联合异丙托溴铵治疗急性感染性喉炎效果比较[J].武警医学,2017,28(2):143-145.[9]马志华,那尔布力·巴合提别克,阿布来提·阿不都哈尔.肺炎合剂联合阿奇霉素治疗小儿肺炎支原体感染后咳嗽临床观察[J].陕西中医,2017,38(5):629-631.[10]吴云锋,谯敏.布地奈德联合复方异丙托溴铵治疗小儿肺炎支原体感染后咳嗽临床效果观察[J].现代诊断与治疗,2016,27(1):75-77.[11]韦新建.复方异丙托溴铵溶液联合布地奈德混悬液雾化吸入治疗哮喘性支气管炎的疗效观察[J].实用中西医结合临床,2017(10):56-57.[12]孙晓亮,王菲.复方异丙托溴铵雾化吸入治疗小儿哮喘的疗效观察[J].中国继续医学教育,2016,8(4):175-176.[13]张晓敏.雾化吸入联合孟鲁司特治疗小儿感染后咳嗽疗效分析[J].淮海医药,2018,36(3):341-343.[14]李涛,张海波,唐静,等.沙丁胺醇、布地奈德辅助雾化吸入治疗小儿哮喘合并呼吸道病毒感染的疗效及预后观察[J].临床和实验医学杂志,2020,19(19):2070-2074.[15]秦艳,姜和.雾化吸入联合孟鲁斯特治疗小儿感染后咳嗽疗效观察[J].中西医结合心血管病电子杂志,2017,5(32):73,76.[16]黄健,温伟溪,丘惠娴.复方异丙托溴铵气雾剂联合布地奈德混悬液雾化吸入对支气管肺炎患儿血清IGF-Ⅱ、PCT水平变化的影响[J].中国妇幼保健,2019,34(5):1051-1054.[17]何勇波,肖戎,缪华.雾化吸入联合孟鲁斯特治疗小儿感染后咳嗽疗效[J].医学理论与实践,2017,30(20):3025-3026.[18]唐群兰.早期吸入布地奈德混悬液预防小儿支原体感染后咳嗽的效果分析[J].黑龙江医药,2018,31(3):555-557.[19]孙远南,陆明荣,倪慧.右美沙芬缓释混悬液联合孟鲁司特钠治疗感染后咳嗽的临床疗效分析[J].中华医院感染学杂志,2016,26(17):3936-3938.

相似文献/References:

[1]周 佳,柴明思.布地奈德、异丙托溴铵气雾剂联合雾化吸入治疗对肺气肿患者肺功能及血液相关指标的影响[J].医学信息,2019,32(09):151.[doi:10.3969/j.issn.1006-1959.2019.09.050]
　ZHOU Jia,CHAI Ming-si.Effects of Budesonide and Ipratropium Bromide Aerosol Combined with Nebulized Inhalation on Pulmonary Function and Blood Related Indexes in Patients with Emphysema[J].Medical Information,2019,32(12):151.[doi:10.3969/j.issn.1006-1959.2019.09.050]
[2]刘江海.异丙托溴铵雾化吸入治疗慢阻肺急性加重期的临床疗效[J].医学信息,2019,32(20):150.[doi:10.3969/j.issn.1006-1959.2019.20.047]
　LIU Jiang-hai.Clinical Efficacy of Ipratropium Bromide Inhalation in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Medical Information,2019,32(12):150.[doi:10.3969/j.issn.1006-1959.2019.20.047]
[3]曹进明.噻托溴铵与异丙托溴铵治疗慢阻肺的效果及对患者血清炎症因子的影响[J].医学信息,2022,35(21):131.[doi:10.3969/j.issn.1006-1959.2022.21.034]
　CAO Jin-ming.Effect of Tiotropium Bromide and Ipratropium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease and its Effect on Serum Inflammatory Factors[J].Medical Information,2022,35(12):131.[doi:10.3969/j.issn.1006-1959.2022.21.034]
[4]陈平兰.布地奈德混悬液联合异丙托溴铵雾化吸入治疗小儿支气管炎临床疗效与安全性研究[J].医学信息,2023,36(08):147.[doi:10.3969/j.issn.1006-1959.2023.08.032]
　CHEN Ping-lan.Study on Clinical Efficacy and Safety of Budesonide Suspension Combined with Ipratropium Bromide Aerosol Inhalation in the Treatment of Bronchitis in Children[J].Medical Information,2023,36(12):147.[doi:10.3969/j.issn.1006-1959.2023.08.032]
[5]张广平.孟鲁司特钠治疗病毒性小儿哮喘的临床疗效及安全性[J].医学信息,2021,34(23):105.[doi:10.3969/j.issn.1006-1959.2021.23.030]
　ZHANG Guang-ping.Clinical Efficacy and Safety of Montelukast Sodium in the Treatment of Viral Asthma in Children[J].Medical Information,2021,34(12):105.[doi:10.3969/j.issn.1006-1959.2021.23.030]

更新日期/Last Update: 1900-01-01